Day 1 :
Keynote Forum
Nehir Ozdemir Ozgenturk
Yildiz Technical University, Turkey
Keynote: Pathways and co-expression network analysis of immune-related genes in shortterm calorie restricted mice
Biography:
Nehir Ozdemır Ozgenturk completed her Graduation at Ege University; Master's degree in Plant Breeding department and; PhD in Department of Justus Liebieg University.In 2003, she worked at Cereal Research Center in Canada as a Post doc. Also she worked at Georgia Medical School for four months with Nato fellowship. She hasscientifi c paper in various scientifi c journals, publications and presentations at international conferences.
Abstract:
RNA-seq technology was performed by using a comparative transcriptome analysis of the MMTV-TGF-α female mice thymus tissues that were fed ad libitum (AL), chronic calorie restriction (CCR) (85% of AL fed mice) and intermittent calorie restriction (ICR) (3 weeks AL fed, 1 week 40% of AL fed mice) from 10 weeks of age to 17 weeks of age or 18 weeks of age. Th e results of RNA-seq analysis, a total of 6091 signifi cantly diff erentially expressed genes (DEGs) were identifi ed. 2821, 2825 and 445 signifi cantly DEGs were detected between AL-CCR, CCR-ICR and AL-ICR fed groups, respectively. Th ese DEGs were classifi ed according to cellular components, biological processes and molecular functions Gene Ontology (GO) main categories. 188 of 2821, 36 of 445, 176 of 2825 genes were identifi ed to be involved in immune system process (GO:0002376) biological processes GO categories. KEGG pathway and the gene co-expression network analysis between AL-CCR, CCRICR and AL-ICR fed groups immune-related DEGs were done using String database. For network analysis, nodes and edgespresented the interaction between immune-related DEGs.
Keynote Forum
Mamoru Shoji
Emory University School of Medicine, USA
Keynote: Inhibition of breast cancer bone metastasis and pancreatic and colon cancer by synthetic curcumin analogue UBS109
Time : 10.40.11.20
Biography:
Mamoru Shojiobtained his Medical Degree from the Hokkaido University, Japan, and completed internships at the US Naval Hospital, Yokosuka, Japan and the University of Pennsylvania in Philadelphia. He did his residency in Internal Medicine at the Lahey Clinic, Boston and fellowship training in Immunology at the Peter Bent Brigham and Robert Breck Brigham Hospitals (mentor, John R David, MD), Harvard Medical School in Boston, in Tumor Immunology at the University of Minnesota (mentor, Charles F Mckhann, MD from Massachusetts General Hospital) in Minneapolis, followed by fellowship in Hematology and Medical Oncology at Emory University (mentor, Charles M Huguley, Jr., MD).
Abstract:
Therapy of breast cancer metastasis with UBS109:An estimated 30% of women diagnosed with invasive breast cancer will have a recurrence and may eventually die of their disease. An estimated 90% of deaths due to breast cancer area consequence of metastatic disease. Bone is one of the most common sites (70%) of metastasis.Monocarbonyl analogs of curcumin (MACs) include UBS109, EF31 and EF24. UBS109 inhibited bone destruction induced by triple-negative breast cancer (TNBC) MDA-MB-231 cells. UBS109 directly stimulates osteoblastogenesis and mineralization in bone marrow cells from normal nude mice in vitro and stimulates osteoblast activation in preosteoblastic cells. Furthermore,UBS109 suppresses the diff erentiation of osteoclast precursors into mature osteoclasts. UBS109 inhibited breast cancer in the bone, osteolysis by inhibiting osteoclast precursors and osteoclasts, but promotes new bone formation by stimulating osteoblast activation. Recently, we have demonstrated that UBS109 inhibited lung metastasis of the TNBC. Novel therapy for pancreaticand colon cancer using UBS109: Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cause of cancer death, theoverall 5-year survival for PDA is less than 5%, a median survival of 4–6 months. Pancreatic cancer (PC) has a high incidence of clotting complications. We tested the cytotoxic activity of UBS109, EF31, EF24, HSP90 inhibitor, gemcitabine (current treatment), Akt inhibitor and p38 MAPK inhibitor against four diff erent PC cells.UBS109 and EF24 inhibited 100% at less than 1.25 μM, but others did not inhibit 100% at concentrations up to 20 μM. UBS109 and EF31(25 mg/kg, I.V.)/week for 3 weeks signifi cantly inhibited MiaPaCa-2 xenograft s in mice.UBS109 (25 mg/kg, I.V.)/week inhibited colon cancer (HT-29 and HCT- 116) xenograft s better than a combination of oxaliplatin (5 mg/kg) and 5FU (30 mg/kg) I.V.
Keynote Forum
Mamoru Shoji
Emory University School of Medicine, USA
Keynote: Inhibition of breast cancer bone metastasis and pancreatic and colon cancer by synthetic curcumin analogue UBS109
Time : 10.40.11.20
Biography:
Mamoru Shojiobtained his Medical Degree from the Hokkaido University, Japan, and completed internships at the US Naval Hospital, Yokosuka, Japan and the University of Pennsylvania in Philadelphia. He did his residency in Internal Medicine at the Lahey Clinic, Boston and fellowship training in Immunology at the Peter Bent Brigham and Robert Breck Brigham Hospitals (mentor, John R David, MD), Harvard Medical School in Boston, in Tumor Immunology at the University of Minnesota (mentor, Charles F Mckhann, MD from Massachusetts General Hospital) in Minneapolis, followed by fellowship in Hematology and Medical Oncology at Emory University (mentor, Charles M Huguley, Jr., MD).
Abstract:
Therapy of breast cancer metastasis with UBS109:An estimated 30% of women diagnosed with invasive breast cancer will have a recurrence and may eventually die of their disease. An estimated 90% of deaths due to breast cancer area consequence of metastatic disease. Bone is one of the most common sites (70%) of metastasis.Monocarbonyl analogs of curcumin (MACs) include UBS109, EF31 and EF24. UBS109 inhibited bone destruction induced by triple-negative breast cancer (TNBC) MDA-MB-231 cells. UBS109 directly stimulates osteoblastogenesis and mineralization in bone marrow cells from normal nude mice in vitro and stimulates osteoblast activation in preosteoblastic cells. Furthermore,UBS109 suppresses the diff erentiation of osteoclast precursors into mature osteoclasts. UBS109 inhibited breast cancer in the bone, osteolysis by inhibiting osteoclast precursors and osteoclasts, but promotes new bone formation by stimulating osteoblast activation. Recently, we have demonstrated that UBS109 inhibited lung metastasis of the TNBC. Novel therapy for pancreaticand colon cancer using UBS109: Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cause of cancer death, theoverall 5-year survival for PDA is less than 5%, a median survival of 4–6 months. Pancreatic cancer (PC) has a high incidence of clotting complications. We tested the cytotoxic activity of UBS109, EF31, EF24, HSP90 inhibitor, gemcitabine (current treatment), Akt inhibitor and p38 MAPK inhibitor against four diff erent PC cells.UBS109 and EF24 inhibited 100% at less than 1.25 μM, but others did not inhibit 100% at concentrations up to 20 μM. UBS109 and EF31(25 mg/kg, I.V.)/week for 3 weeks signifi cantly inhibited MiaPaCa-2 xenograft s in mice.UBS109 (25 mg/kg, I.V.)/week inhibited colon cancer (HT-29 and HCT- 116) xenograft s better than a combination of oxaliplatin (5 mg/kg) and 5FU (30 mg/kg) I.V.